Results 1 to 10 of about 12,338 (219)
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma [PDF]
Haematologica, 2015 Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos +13 more
doaj +5 more sources
Characterization of bortezomib-adapted I-45 mesothelioma cells [PDF]
Molecular Cancer, 2010 Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander +5 more
doaj +2 more sources
Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations [PDF]
Biomolecules, 2021 Bortezomib (BTZ) is the first proteasome inhibitor approved by the Food and Drug Administration. It can bind to the amino acid residues of the 26S proteasome, thereby causing the death of tumor cells. BTZ plays an irreplaceable role in the treatment of mantle cell lymphoma and multiple myeloma.
Jianhao Liu +4 more
openaire +3 more sources
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]
PLoS ONE, 2013 Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu +6 more
doaj +1 more source
Molecules, 2023 Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the possibility of interaction between bortezomib and cellular components ...
Mihaela-Cristina Bunea +2 more
doaj +1 more source
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
Neoplasia: An International Journal for Oncology Research, 2022 The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett +12 more
doaj +1 more source
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. [PDF]
PLoS ONE, 2013 Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored.
Julia S Gelman +7 more
doaj +1 more source
Breathless on bortezomib [PDF]
BMJ Case Reports, 2011 The authors describe a case of episodic acute pneumonitis occurring after repeated doses of bortezomib, a drug being used increasingly to treat multiple myeloma. The delay in presentation each time with fever, dyspnoea, hypoxia and interstitial radiological changes contributed to under-recognition of this complication, which has so far been described ...
Devaki, O'Riordan +3 more
openaire +2 more sources
Asian Journal of Oncology, 2022 Objectives Bortezomib vial-sharing is commonly employed to maximize the treatment of patients with multiple myeloma (MM) in resource-limited setting. This strategy minimizes delays in treatment but reduces the dose of bortezomib received by the patient ...
Jeremiah R. Vallente +2 more
doaj +1 more source
Journal of Hematology & Oncology, 2018 Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng +7 more
doaj +1 more source